Corteva, Inc. today announced that its Board of Directors authorized a new $3 billion share repurchase program. The authorization is immediately effective, does not expire, and gives management ...

As an influential advocate for Indigenous peoples’ rights, Jeannette Armstrong has been a force of change and wide-scale ...

Agentic AI has the potential to reshape not just healthcare, but the very foundations of biological research. By allowing autonomous systems to explore the unknown, we may unlock new levels of ...

Sanofi has made numerous investments in AI, inking pacts with partners such as Owkin and Exscientia. The French major has ...

Else Kroener Fresenius Center for Digital Health, Technical University Dresden, Dresden, Germany; and Department of Medicine II, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany ...

This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license. This work is licensed under a Creative Commons ...

Owkin, the first end-to-end AI-biotech that uses cutting-edge causal AI to unlock precision drug discovery, development, and diagnostics, has announced MSIntuit CRC v21, a next-generation AI solution.

Meriem Sefta, PhD, Chief Diagnostics Officer of Owkin, said: “We are thrilled to bring the next innovations in MSIntuit ® CRC to pathology labs, marking a significant advancement in the field of ...

Owkin, the first end-to-end AI-biotech that uses cutting-edge causal AI to unlock precision drug discovery, development, and diagnostics has announced MSIntuit ® CRC v2 1, a next-generation AI ...

A Research Use Only (RUO) version will launch on Roche’s navify® Digital Pathology enterprise software, an application for the pathologist’s workflow aimed to support pathologists and ...